Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL (12mg and 4mg/mL),Sing...

FDA Drug Recall #D-0097-2026 — Class II — October 21, 2025

Recall Summary

Recall Number D-0097-2026
Classification Class II — Moderate risk
Date Initiated October 21, 2025
Status Ongoing
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Bristol-Myers Squibb Company
Location New Brunswick, NJ
Product Type Drugs
Quantity 12,778 total vials

Product Description

Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL (12mg and 4mg/mL),Single Dose Vial, RX Only, Bristol-Myers Squibb Company, Princeton, NJ 08543, NDC 0003-7125-11

Reason for Recall

Lack of Assurance of Sterility.

Distribution Pattern

Nationwide in the USA

Lot / Code Information

Lot: 033A23B, Expiry: 4/30/2026

Other Recalls from Bristol-Myers Squibb Company

Recall # Classification Product Date
D-0959-2017 Class I EliquisTablets 5mg, 60 count bottle, Rx Only, M... Jun 5, 2017
D-012-2013 Class I BiCNU (Carmustine for injection) 100 mg and Di... Aug 29, 2012
D-019-2013 Class II Kombiglyze XR (saxagliptin and metformin HCl ex... Jun 5, 2012
D-018-2013 Class II Kombiglyze XR (saxagliptin and metformin HCl ex... Jun 5, 2012

Frequently Asked Questions

Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.